心不全における制御RNA
Clarissa Pedrosa Costa Gomes1, Blanche Schroen2, Gabriela M Kuster3
1Cardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg (C.P.d.C.G., Y.D.).
Circulation
|January 28, 2020
まとめ
メッセンジャーRNAとノンコーディングRNAを含むレギュレータRNAは,心不全における遺伝子発現に不可欠である. その役割を理解することで 心血管疾患の新たな診断と治療戦略が生まれます
科学分野:
- 心血管生物学
- 分子遺伝学
- RNA生物学
背景:
- 心血管疾患 特に心不全は 世界的な健康問題です
- 遺伝子発現の調節は心臓の恒常性を維持するために重要です.
- 配列と非配列の両方のRNA分子は この調節において重要な役割を果たします
研究 の 目的:
- タンパク質をコードするRNAと非コードするRNAの両方を含むように,規制RNA (regRNA) の概念を広げる.
- 心不全における様々なレグRNAの調節と機能を検討する.
- 心不全の診断,予後,治療におけるレグRNAの可能性を調査する.
主な方法:
- 規制RNAに関する既存の研究の文献レビューと合成.
- 心不全におけるメッセンジャーRNA,マイクロRNA,ロングノンコーディングRNA,円形RNAの役割の分析.
- レグRNA研究の臨床的有用性と将来の方向性についての議論.
主要な成果:
- 調節性RNA (regRNAs) は,遺伝子発現に影響を与えるタンパク質をコードするRNA分子と非コードするRNA分子を両方含む.
- mRNA,miRNA,lncRNA,circRNAを含む特定のregRNAは,心不全の病理生理学に関与しています.
- これらのレグRNAは,心血管疾患のバイオマーカーおよび治療標的としての可能性を秘めています.
結論:
- 調節性RNAの定義は,遺伝子発現制御に関与するすべてのRNA種を含むように拡張されるべきである.
- メッセンジャーRNA,マイクロRNA,ロングノンコーディングRNA,円形RNAは心不全の発達と進行に不可欠です.
- レグRNAのさらなる調査は,心臓不全の診断と治療を進めるのに有望である.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
842
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
842
01:29Heart Failure II: Pathophysiology
603
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
603
01:30Heart Failure V: Medical Management
166
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
166
01:31Regulation of Heart Rates
3.6K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
3.6K
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:22Heart Failure Drugs: β-Blockers
697
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
697